Rezolute Inc - Asset Resilience Ratio
Rezolute Inc (RZLT) has an Asset Resilience Ratio of 86.91% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Rezolute Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Rezolute Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see RZLT total asset value.
Liquid Assets Composition Over Time
This chart breaks down Rezolute Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Rezolute Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $109.03 Million | 86.91% |
| Total Liquid Assets | $109.03 Million | 86.91% |
Asset Resilience Insights
- Very High Liquidity: Rezolute Inc maintains exceptional liquid asset reserves at 86.91% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Rezolute Inc Industry Peers by Asset Resilience Ratio
Compare Rezolute Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Rezolute Inc (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Rezolute Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 42.03% | $73.75 Million | $175.49 Million | -0.52pp |
| 2024-06-30 | 42.55% | $56.48 Million | $132.74 Million | -26.85pp |
| 2023-06-30 | 69.40% | $85.86 Million | $123.72 Million | -- |
| 2022-06-30 | 0.00% | $0.00 | $152.42 Million | -- |
| 2015-06-30 | 4.00% | $450.00K | $11.26 Million | -- |
About Rezolute Inc
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for th… Read more